US Patent Issued to GENSIGHT BIOLOGICS on Oct. 27 for "Recombinant AAV vectors and methods of using the same" (American, French Inventors)

ALEXANDRIA, Va., Oct. 27 -- United States Patent no. 12,774,473, issued on Oct. 27, was assigned to GENSIGHT BIOLOGICS SA (Paris).

"Recombinant AAV vectors and methods of using the same" was invented by Serge Fitoussi (Saint Maur des Fosses, France) and Barrett Katz (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to recombinant vectors expressing the human ND4 gene, methods of preparing recombinant vectors expressing the human ND4 gene, and uses thereof. Recombinant AAV2 vectors as disclosed herein are useful in treating Leber Hereditary Optic Neuroretinopathy (LHON), including ND4-related LHON."

The patent was filed on June 11, 2019, under Application No. 16/973,900....